Flores Raja M, Pass Harvey I, Seshan Venkatraman E, Dycoco Joseph, Zakowski Maureen, Carbone Michele, Bains Manjit S, Rusch Valerie W
Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3. doi: 10.1016/j.jtcvs.2007.10.054. Epub 2008 Feb 14.
The optimal procedure for resection of malignant pleural mesothelioma is controversial, partly because previous analyses include small numbers of patients. We performed a multi-institutional study to increase statistical power to detect significant differences in outcome between extrapleural pneumonectomy and pleurectomy/decortication.
Patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy or pleurectomy/decortication at 3 institutions were identified. Survival and prognostic factors were analyzed by the Kaplan-Meier method, log-rank test, and Cox proportional hazards analysis.
From 1990 to 2006, 663 consecutive patients (538 men and 125 women) underwent resection. The median age was 63 years (range, 26-93 years). The operative mortality was 7% for extrapleural pneumonectomy (n = 27/385) and 4% for pleurectomy/decortication (n = 13/278). Significant survival differences were seen for American Joint Committee on Cancer stages 1 to 4 (P < .001), epithelioid versus non-epithelioid histology (P < .001), extrapleural pneumonectomy versus pleurectomy/decortication (P < .001), multimodality therapy versus surgery alone (P < .001), and gender (P < .001). Multivariate analysis demonstrated a hazard rate of 1.4 for extrapleural pneumonectomy (P < .001) controlling for stage, histology, gender, and multimodality therapy.
Patients who underwent pleurectomy/decortication had a better survival than those who underwent extrapleural pneumonectomy; however, the reasons are multifactorial and subject to selection bias. At present, the choice of resection should be tailored to the extent of disease, patient comorbidities, and type of multimodality therapy planned.
恶性胸膜间皮瘤的最佳切除手术存在争议,部分原因是既往分析纳入的患者数量较少。我们开展了一项多机构研究,以增强统计效力,从而发现胸膜外全肺切除术与胸膜剥脱术/去皮质术在预后方面的显著差异。
确定在3家机构接受胸膜外全肺切除术或胸膜剥脱术/去皮质术的恶性胸膜间皮瘤患者。采用Kaplan-Meier法、对数秩检验和Cox比例风险分析对生存情况和预后因素进行分析。
1990年至2006年,连续663例患者(538例男性和125例女性)接受了手术切除。中位年龄为63岁(范围26 - 93岁)。胸膜外全肺切除术(n = 27/385)的手术死亡率为7%,胸膜剥脱术/去皮质术(n = 13/278)的手术死亡率为4%。美国癌症联合委员会1至4期(P < .001)、上皮样与非上皮样组织学类型(P < .001)、胸膜外全肺切除术与胸膜剥脱术/去皮质术(P < .001)、多模式治疗与单纯手术(P < .001)以及性别(P < .001)在生存方面存在显著差异。多变量分析显示,在控制分期、组织学类型、性别和多模式治疗的情况下,胸膜外全肺切除术的风险比为1.4(P < .001)。
接受胸膜剥脱术/去皮质术的患者比接受胸膜外全肺切除术的患者生存情况更好;然而,原因是多因素的且存在选择偏倚。目前,切除手术的选择应根据疾病范围、患者合并症以及计划的多模式治疗类型进行调整。